Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 11, 2026, 5:23 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 6,152 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Study Drug Placebo Clear all
Recruiting Phase 2 Interventional

The Purpose of This Study is to Evaluate Efficacy and Safety of NT-101 Eye Drops in Patients With Wet Age-Related Macular Degeneration (AMD)

NCT07811726
View directory record Official record
Conditions
Wet Age Related Macular Degeneration
Interventions
NT-101 ophthalmic solution, Placebo
Drug
Lead sponsor
NexThera Co., Ltd.
Industry
Eligibility
50 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
3
States / cities
Bonita Springs, Florida • Tulsa, Oklahoma • Erie, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Sep 11, 2026, 5:23 PM EDT
Completed Phase 3 Interventional Results available

A Safety, Efficacy and Tolerability Trial of Pregabalin as Add-On Treatment in Pediatric and Adult Subjects With Primary Generalized Tonic-Clonic (i.e., Grand Mal) Seizures.

NCT01747915
View directory record Official record
Conditions
Generalized Tonic Clonic Seizures
Interventions
Pregabalin Dose Level 1, Pregabalin Dose Level 2, Placebo
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
5 Years to 65 Years
Enrollment
219 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
12
States / cities
Loxahatchee Groves, Florida • Orlando, Florida • Port Charlotte, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Jan 19, 2021 · Synced Sep 11, 2026, 5:23 PM EDT
Completed Phase 3 Interventional Results available

Long-term Follow-up Study With Darvadstrocel in the Treatment of Complex Perianal Fistula

NCT04075825
View directory record Official record
Conditions
Crohn's Disease, Complex Perianal Fistula
Interventions
Placebo, Darvadstrocel
Other · Biological
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
22
States / cities
San Francisco, California • West Hollywood, California • New Haven, Connecticut + 17 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2025 · Synced Sep 11, 2026, 5:23 PM EDT
Completed Phase 3 Interventional Results available

Efficacy of Tenofovir Alafenamide Versus Placebo Added to a Failing Regimen Followed by Treatment With Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Plus Atazanavir in HIV-1 Positive, Antiretroviral Treatment-Experienced Adults

NCT01967940
View directory record Official record
Conditions
HIV, HIV Infections, Acquired Immunodeficiency Syndrome
Interventions
TAF, Placebo, E/C/F/TAF, Current failing ARV regimen, ATV
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
5
States / cities
Ft. Pierce, Florida • West Palm Beach, Florida • Wilton Manors, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 15, 2018 · Synced Sep 11, 2026, 5:23 PM EDT
Withdrawn Phase 2 Interventional

Pilot Study to Compare Topical Voriconazole to Placebo as a Pain Reducing Agent

NCT02689713
View directory record Official record
Conditions
Pain, Thermal Injury, Burns, Hyperalgesia
Interventions
Voriconazole (topical), Topical Sterile Water Placebo Group
Drug
Lead sponsor
Kenneth Hargreaves
Other
Eligibility
18 Years to 60 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Dec 16, 2018 · Synced Sep 11, 2026, 5:23 PM EDT
Completed Phase 2 Interventional Results available

Evaluation of Dupilumab's Effects on Airway Inflammation in Patients With Asthma

NCT02573233
View directory record Official record
Conditions
Asthma
Interventions
Placebo, Dupilumab SAR231893/REGN668, fluticasone propionate and salmeterol, budesonide and formoterol, mometasone furoate and formoterol
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 65 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
6
States / cities
Tucson, Arizona • Denver, Colorado • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2022 · Synced Sep 11, 2026, 5:23 PM EDT
Withdrawn Phase 2Phase 3 Interventional

Safety and Efficacy of Perioperative Remodulin® in Orthotopic Liver Transplant Recipients

NCT01884038
View directory record Official record
Conditions
Liver Transplant
Interventions
treprostinil sodium, Placebo
Drug
Lead sponsor
United Therapeutics
Industry
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 18, 2023 · Synced Sep 11, 2026, 5:23 PM EDT
Completed Phase 2 Interventional Results available

A Study to Investigate the Efficacy and Safety of GSK3196165 in Inflammatory Hand Osteoarthritis

NCT02683785
View directory record Official record
Conditions
Osteoarthritis
Interventions
GSK3196165, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
2
States / cities
Miami, Florida • Duncansville, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 10, 2021 · Synced Sep 11, 2026, 5:23 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Lubiprostone, Colonic Motility and Sensation

NCT00953043
View directory record Official record
Conditions
Healthy
Interventions
lubiprostone, Placebo, Bowel preparation
Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 26, 2012 · Synced Sep 11, 2026, 5:23 PM EDT
Completed Phase 2 Interventional Results available

A Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of TERN-601 in Adults With Overweight or Obesity

NCT06854952
View directory record Official record
Conditions
Overweight or Obesity
Interventions
TERN-601, Matching Placebo
Drug · Other
Lead sponsor
Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years to 75 Years
Enrollment
167 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
17
States / cities
Birmingham, Alabama • Homewood, Alabama • Tucson, Arizona + 14 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2026 · Synced Sep 11, 2026, 5:23 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Assess the Effects of Daily Administration of Pioglitazone on Brain Hemodynamics in Healthy Elderly Participants

NCT01456117
View directory record Official record
Conditions
Healthy
Interventions
Pioglitazone, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
55 Years to 83 Years
Enrollment
61 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 7, 2012 · Synced Sep 11, 2026, 5:23 PM EDT
Completed Phase 4 Interventional Results available

The Effect of Dupilumab on Lung Inflammation and Related Changes in Airway Volumes Detectable by Functional Respiratory Imaging in Patients With Moderate-severe Asthma

NCT04400318
View directory record Official record
Conditions
Asthma
Interventions
Dupilumab, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 70 Years
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
10
States / cities
Westminster, California • Kansas City, Kansas • Ann Arbor, Michigan + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2025 · Synced Sep 11, 2026, 5:23 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

First in Human Study for Safety and Tolerability of AL003.

NCT03822208
View directory record Official record
Conditions
Healthy, Alzheimer Disease
Interventions
AL003, Saline Solution
Biological · Other
Lead sponsor
Alector Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
5
States / cities
Delray Beach, Florida • Lady Lake, Florida • Orlando, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2021 · Synced Sep 11, 2026, 5:23 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy Study for a New Antiviral Drug to Treat Genital Herpes Type 2

NCT01047540
View directory record Official record
Conditions
HSV-2
Interventions
AIC316, Placebo
Drug
Lead sponsor
AiCuris Anti-infective Cures AG
Industry
Eligibility
18 Years and older
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
6
States / cities
Miami, Florida • Indianapolis, Indiana • Portland, Oregon + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2023 · Synced Sep 11, 2026, 5:23 PM EDT
Completed Phase 4 Interventional Results available

A Study to Evaluate the Efficacy of Lastacaft® Compared to Pataday™ and Placebo in Patients With Acute Allergic Conjunctivitis

NCT01732757
View directory record Official record
Conditions
Conjunctivitis, Allergic
Interventions
Alcaftadine 0.25%, Olopatadine 0.2%, dextran 70 0.1%/hydroxypropyl methylcellulose 0.3%
Drug
Lead sponsor
Allergan
Industry
Eligibility
10 Years and older
Enrollment
157 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 13, 2014 · Synced Sep 11, 2026, 5:23 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Trial of Rosiglitazone for Ulcerative Colitis

NCT00065065
View directory record Official record
Conditions
Ulcerative Colitis, Inflammatory Bowel Disease
Interventions
Rosiglitazone, Placebo
Drug
Lead sponsor
James Lewis
Other
Eligibility
18 Years and older
Enrollment
105 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2008
U.S. locations
13
States / cities
Atlanta, Georgia • Chicago, Illinois • Chevy Chase, Maryland + 9 more
Source: ClinicalTrials.gov public record
Updated Jan 15, 2018 · Synced Sep 11, 2026, 5:23 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability and Immune Effects of the Nasal Foralumab in Healthy Human Volunteers

NCT06879067
View directory record Official record
Conditions
Safety, Tolerability
Interventions
Placebo, Foralumab Nasal
Drug
Lead sponsor
Tiziana Life Sciences LTD
Industry
Eligibility
18 Years to 65 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 16, 2025 · Synced Sep 11, 2026, 5:23 PM EDT
Active, not recruiting Phase 2 Interventional

A Research Study on How Well Different Doses of the Medicine NNC0662-0419 Help People Living With Overweight or Obesity

NCT07184632
View directory record Official record
Conditions
Overweight, Obesity
Interventions
NNC0662-0419, Placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 65 Years
Enrollment
224 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
2
States / cities
Tempe, Arizona • Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Sep 11, 2026, 5:23 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Study of d-MAPPS™ Ophthalmic Solution, Safety, Tolerability, and Efficacy in the Treatment of Chronic Ocular Graft-Versus-Host Disease (oGVHD)

NCT06852768
View directory record Official record
Conditions
oGHVD
Interventions
d-MAPPS, Placebo, PI and Patient Masked
Biological · Other
Lead sponsor
Regenerative Ocular Immunobiologics LLC
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
6
States / cities
Beverly Hills, California • Huntington Beach, California • Palm Harbor, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Sep 11, 2026, 5:23 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Progesterone for the Management of Preterm, Premature Rupture of the Membranes: A Randomized Controlled Trial.

NCT01050647
View directory record Official record
Conditions
Pregnancy Complications
Interventions
17-Hydroxyprogesterone Caproate, Caster Oil injections
Drug · Other
Lead sponsor
Stanford University
Other
Eligibility
Female only
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
2
States / cities
San Jose, California • Stanford, California
Source: ClinicalTrials.gov public record
Updated Apr 8, 2019 · Synced Sep 11, 2026, 5:23 PM EDT
Completed Phase 3 Interventional Results available

A Safety and Efficacy Study of Beclomethasone Dipropionate Delivered Via Breath-Actuated Inhaler (BAI) or Metered-Dose Inhaler (MDI) in Participants >=12 Years Old With Persistent Asthma

NCT02031640
View directory record Official record
Conditions
Asthma
Interventions
Beclomethasone dipropionate, Placebo, Albuterol/salbutamol
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
12 Years and older
Enrollment
1,113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
94
States / cities
Costa Mesa, California • Huntington Beach, California • Long Beach, California + 77 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2021 · Synced Sep 11, 2026, 5:23 PM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Effects of Progesterone on IV Nicotine Induced Changes on BOLD fMRI Signal, Hormones and Subjective Ratings of Stimulant Drugs

NCT01589068
View directory record Official record
Conditions
Nicotine Dependence
Interventions
Intravenous Nicotine, Progesterone
Drug
Lead sponsor
Mclean Hospital
Other
Eligibility
18 Years to 40 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2015
U.S. locations
1
States / cities
Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 16, 2024 · Synced Sep 11, 2026, 5:23 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Safety, Tolerability, Drug Levels and Drug Effects of BMS-986331 in Healthy Participants

NCT04444050
View directory record Official record
Conditions
Healthy Participants
Interventions
BMS-986331, Placebo, Matching BMS-986331
Drug · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
2
States / cities
Anaheim, California • Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Oct 19, 2022 · Synced Sep 11, 2026, 5:23 PM EDT
Terminated Phase 3 Interventional Results available

Tivantinib Plus Erlotinib Versus Placebo Plus Erlotinib for the Treatment of Non-squamous, Non-small-cell Lung Cancer

NCT01244191
View directory record Official record
Conditions
Non Squamous, Non-small-cell Lung Cancer
Interventions
Tivantinib, Placebo, Erlotinib
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
1,048 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
111
States / cities
Tucson, Arizona • Los Angeles, California • Oxnard, California + 85 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2021 · Synced Sep 11, 2026, 5:23 PM EDT